- Home
- FOA vs ALDX Comparison
FOA vs ALDX Comparison
Compare FOA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- ALDX
- Stock Information
- Founded
- FOA 2013
- ALDX 2004
- Country
- FOA United States
- ALDX United States
- Employees
- FOA N/A
- ALDX N/A
- Industry
- FOA Finance Companies
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- ALDX Health Care
- Exchange
- FOA Nasdaq
- ALDX Nasdaq
- Market Cap
- FOA 272.8M
- ALDX 314.6M
- IPO Year
- FOA N/A
- ALDX 2014
- Fundamental
- Price
- FOA $22.71
- ALDX $5.14
- Analyst Decision
- FOA Buy
- ALDX Strong Buy
- Analyst Count
- FOA 2
- ALDX 2
- Target Price
- FOA $27.50
- ALDX $9.50
- AVG Volume (30 Days)
- FOA 122.0K
- ALDX 666.3K
- Earning Date
- FOA 11-04-2025
- ALDX 11-06-2025
- Dividend Yield
- FOA N/A
- ALDX N/A
- EPS Growth
- FOA N/A
- ALDX N/A
- EPS
- FOA 7.10
- ALDX N/A
- Revenue
- FOA $527,520,999.00
- ALDX N/A
- Revenue This Year
- FOA $21.21
- ALDX N/A
- Revenue Next Year
- FOA $10.95
- ALDX $63.48
- P/E Ratio
- FOA $3.20
- ALDX N/A
- Revenue Growth
- FOA 46.94
- ALDX N/A
- 52 Week Low
- FOA $11.33
- ALDX $1.14
- 52 Week High
- FOA $32.40
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- FOA 48.19
- ALDX 44.60
- Support Level
- FOA $22.38
- ALDX $5.06
- Resistance Level
- FOA $23.21
- ALDX $5.40
- Average True Range (ATR)
- FOA 0.83
- ALDX 0.29
- MACD
- FOA 0.22
- ALDX -0.03
- Stochastic Oscillator
- FOA 69.15
- ALDX 40.58
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.